How to Get Low-Dose Naltrexone in Ohio

What Low-Dose Naltrexone Is and Why Ohio Patients Seek It

Low-dose naltrexone refers to naltrexone hydrochloride taken at doses between 1.5 mg and 4.5 mg per night. That range is one-tenth to one-fifth of the 50 mg dose the FDA approved in 1984 for opioid use disorder. At sub-pharmacological doses, the short opioid-receptor blockade that occurs during sleep appears to trigger a rebound upregulation of endogenous opioid production and a simultaneous reduction in microglial activation. The net effect is an anti-inflammatory and potentially analgesic outcome that standard naltrexone dosing does not produce.

The Clinical Evidence Behind LDN

The signal that generated most early clinical interest came from Younger et al. (2009, N=10), a crossover trial in which LDN at 4.5 mg reduced fibromyalgia symptom scores by 30% compared with placebo 1. A larger follow-up by Younger, Parkitny, and McLain (2014, N=31) in Arthritis Research and Therapy confirmed a 15% reduction in daily pain scores versus placebo, with no serious adverse events recorded across the 16-week trial period 2.

Crohn's disease research has produced parallel findings. Smith et al. (2011, N=40) published in Alimentary Pharmacology and Therapeutics showed that 4.5 mg LDN achieved clinical response in 88% of pediatric Crohn's patients versus 40% on placebo (P<0.001) 3. The anti-inflammatory mechanism under investigation involves toll-like receptor 4 antagonism and reduced NF-kB signaling, pathways studied in detail in Watkins, Hutchinson, and colleagues' NIDA-funded mechanistic work 4.

Why Compounding Is Required

No pharmaceutical manufacturer markets a 1.5 mg to 4.5 mg naltrexone product. Revia (naltrexone 50 mg tablets, Teva) and Vivitrol (naltrexone 380 mg injectable, Alkermes) are the only FDA-approved forms 5. Ohio patients therefore rely entirely on 503A compounding pharmacies to obtain the correct dose. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound naltrexone capsules on a per-patient, prescription-required basis 6.

Ohio Prescribing Rules: Who Can Write the Prescription

Physicians and Osteopathic Physicians

Any MD or DO holding a current, unrestricted Ohio State Medical Board license may prescribe compounded LDN for off-label indications. Ohio Revised Code Section 4731.22 governs medical practice standards; prescribing an off-label compounded drug is permissible as long as the prescriber documents clinical rationale in the patient record 7. No special DEA waiver is needed because naltrexone is not a controlled substance under the Federal Controlled Substances Act or Ohio law.

Nurse Practitioners and Physician Assistants

Ohio NPs with a standard certificate of authority and prescriptive authority from the Ohio Board of Nursing may write Schedule II through V prescriptions independently, effective under Ohio's 2019 Advanced Practice Registered Nurse prescriptive authority expansion. PAs licensed by the State Medical Board may also prescribe under their supervising or collaborating physician's scope. Both provider types are actively prescribing LDN in Ohio telehealth contexts in 2025.

Telehealth Prescribing: What Ohio Law Requires

Ohio's telehealth statute (Ohio Revised Code Section 4743.09), as updated in 2023, allows prescribing after a synchronous audio-video encounter. A prior in-person visit is not required for most non-controlled medications. Because naltrexone is not a controlled substance, LDN prescriptions may be issued after a single qualifying telehealth visit. The prescriber must be licensed in Ohio and the patient must be physically located in Ohio at the time of the visit 8.

Step-by-Step: How to Get an LDN Prescription in Ohio

Step 1. Gather Your Medical History Before the Visit

Prepare a summary of current diagnoses, current medications, and any prior opioid therapy. LDN is contraindicated in patients currently taking opioid analgesics because even low-level receptor blockade can precipitate withdrawal. If you take tramadol, buprenorphine, or codeine-containing products, discuss a taper plan with your prescriber before starting LDN 9.

Step 2. Get Baseline Lab Work

Most Ohio prescribers require the following before initiating LDN:

• Comprehensive metabolic panel (CMP), including liver function tests (AST, ALT, bilirubin)
• Complete blood count (CBC)
• Thyroid-stimulating hormone (TSH) for patients with suspected autoimmune thyroid disease

The liver function panel is clinically significant. Full-dose naltrexone at 50 mg carries an FDA black-box warning for hepatotoxicity 5. Although the substantially lower doses used in LDN therapy have not reproduced that signal in published trials 1, baseline LFTs remain standard practice across most Ohio telehealth platforms and are recommended by the LDN Research Trust clinical guidelines 10.

Most LabCorp and Quest locations across Ohio can run a CMP and CBC without a specialist referral. Results are typically available within 24 to 48 hours.

Step 3. Schedule a Telehealth or In-Person Visit

Search for an Ohio-licensed provider through:

• HealthRX telehealth (Ohio-licensed clinicians, audio-video appointments available within 72 hours)
• The LDN Research Trust provider directory, which lists Ohio prescribers
• The Ohio State Medical Board license verification portal to confirm any provider's active Ohio license

During the visit, your clinician will review your labs, confirm the absence of opioid contraindications, and document a clinical indication. Documented indications used by Ohio prescribers in off-label contexts include fibromyalgia (ICD-10 M79.7), Crohn's disease (ICD-10 K50.x), multiple sclerosis (ICD-10 G35), and chronic fatigue syndrome (ICD-10 R53.82).

Step 4. Send the Prescription to a 503A Compounding Pharmacy

Your prescriber will transmit a prescription to a 503A-licensed compounding pharmacy. The prescription must specify:

• Drug name: naltrexone HCl
• Dose: commonly 1.5 mg, 3.0 mg, or 4.5 mg per capsule
• Quantity: 30 capsules (30-day supply is standard)
• Route: oral
• Directions: one capsule nightly at bedtime

Ohio pharmacies licensed as 503A compounders may fill this prescription directly. Out-of-state 503A pharmacies licensed to ship to Ohio (such as those in Florida, Texas, or Virginia) may also receive and fill the prescription, provided they hold a valid Ohio Board of Pharmacy non-resident pharmacy license 11.

Step 5. Start at a Low Dose and Titrate

Standard titration in published protocols begins at 1.5 mg nightly for 2 weeks, then increases to 3.0 mg for 2 additional weeks, reaching the target dose of 4.5 mg by week 5. The UCSF Multiple Sclerosis Center protocol published in 2021 uses an identical titration schedule 12. Vivid dreams and mild insomnia during the first 2 to 3 weeks are the most commonly reported side effects; both typically resolve without dose adjustment 1.

Ohio 503A Compounding Pharmacies: Rules and Shipping

What 503A Means for Ohio Patients

A 503A pharmacy compounds medications based on individual prescriptions, as opposed to 503B outsourcing facilities that produce batches for hospital use. The FDA does not approve individual 503A compounds, but it does regulate compounding quality standards under the Current Good Manufacturing Practice framework 6. Ohio's State Board of Pharmacy enforces additional state-level standards for in-state 503A pharmacies 11.

Shipping Timelines to Ohio Addresses

Most 503A pharmacies that serve Ohio telehealth patients ship via USPS Priority Mail or UPS Ground. Once a prescription is received and verified:

• Compounding time: 2 to 5 business days
• Shipping to Ohio addresses: 1 to 3 business days

Total time from visit to first capsule is typically 7 to 14 days for new patients using a telehealth-to-pharmacy workflow.

Cost Without Insurance

Ohio Medicaid does not cover LDN for fibromyalgia, autoimmune, or inflammatory conditions. Most commercial insurers also deny coverage, citing the off-label and compounded status. Self-pay pricing at Ohio-accessible 503A pharmacies ranges from $40 to $80 for a 30-capsule supply at 4.5 mg, based on publicly listed pharmacy pricing in 2025. The telehealth visit itself varies; platforms charge $75 to $199 for an initial LDN consultation.

Transferring an Existing LDN Prescription to Ohio

If you have an LDN prescription from another state and you move to or temporarily reside in Ohio, the prescription itself cannot transfer in the traditional sense because compounded medications are not technically a "prescription drug product" you can transfer pharmacy-to-pharmacy. Your previous prescriber may, if licensed in Ohio or willing to refer, send a new prescription to an Ohio-accessible pharmacy. Alternatively, a new Ohio-licensed provider can review your records and issue a fresh prescription without repeating labs if they are less than 6 months old and values were within normal limits.

The Ohio Board of Pharmacy confirmed in 2022 guidance that an out-of-state prescriber not licensed in Ohio may not transmit a prescription for a compounded medication to an Ohio-registered pharmacy for a patient currently in Ohio. An Ohio license is required on the prescriber side 11.

Insurance, Prior Authorization, and Ohio Medicaid

Commercial Insurance Prior Authorization

When a patient or provider attempts to run LDN through commercial insurance in Ohio, the insurer typically requests the following documentation for a prior authorization review:

1. Clinical notes documenting the diagnosis and failure of at least one first-line therapy
2. Lab results (CMP/LFTs) within the past 6 months
3. Letter of medical necessity from the prescribing clinician

Because LDN is compounded rather than manufactured, most commercial insurers issue a blanket exclusion for "compounded medications not equivalent to an FDA-approved product." The prior authorization process rarely succeeds for LDN in Ohio. Patients should plan to pay out of pocket.

Ohio Medicaid: Off-Label Exclusion

Ohio Medicaid's Preferred Drug List, administered by the Ohio Department of Medicaid, covers naltrexone only for opioid use disorder and alcohol use disorder at FDA-approved dosing. The off-label, compounded low-dose formulation is explicitly excluded 13. No MyCare Ohio managed care plan has listed LDN as a covered benefit as of the 2025 formulary year.

Monitoring After Starting LDN in Ohio

Most Ohio telehealth prescribers follow a three-checkpoint monitoring schedule after LDN initiation:

Week 2 check-in (asynchronous or brief video). The prescriber reviews symptom response and screens for vivid dreams, insomnia, or gastrointestinal discomfort. If all three occur simultaneously and are severe, the dose may be held at 1.5 mg for an additional 2 weeks before titrating.

Month 3 lab review. Repeat CMP and LFTs. If AST or ALT rises above 3 times the upper limit of normal, the prescriber should discontinue LDN and investigate other hepatotoxic causes. In published LDN trials, no participant experienced clinically significant liver enzyme elevation at doses below 4.5 mg 2.

Month 6 outcomes review. The prescriber documents whether the patient's primary outcome measure (pain score, disease activity index, fatigue scale) improved by at least 20% from baseline. The 20% threshold aligns with the minimum clinically important difference for the Fibromyalgia Impact Questionnaire, the primary tool used in Younger et al.'s 2009 and 2013 trials 1 14.

If a patient sees no measurable benefit by month 6 on 4.5 mg nightly, the prescriber should reassess the diagnosis and consider discontinuation. LDN does not produce physical dependence, so no taper is needed on discontinuation.

What to Tell Your Ohio Doctor at the First Visit

Patients sometimes arrive at an LDN consultation without framing the request clearly. The following language helps Ohio prescribers document appropriately:

"I have a diagnosed condition of [fibromyalgia / Crohn's disease / multiple sclerosis / autoimmune thyroid disease]. I have tried [specific prior therapy] for [duration] with [inadequate response / intolerable side effects]. I am not currently taking any opioid analgesics. I am requesting a therapeutic trial of compounded low-dose naltrexone at 1.5 mg titrated to 4.5 mg as studied in Younger et al. 2009."

That framing gives the prescriber the elements needed for a defensible off-label prescribing note: diagnosis, treatment history, contraindication screening, and a specific dosing reference. Younger and Mackey (2014) stated directly: "Low dose naltrexone may represent one of the most promising new pharmacological treatments for fibromyalgia, pending large controlled trials" 2. Bringing that reference to the visit demonstrates informed, self-directed research that most Ohio prescribers respond to positively.

Drug Interactions Ohio Patients Should Disclose

The drug interactions relevant to LDN are narrow but serious. Disclose these to your prescriber before starting:

• Opioid analgesics (morphine, oxycodone, hydrocodone, tramadol, tapentadol): absolute contraindication. LDN will precipitate acute withdrawal 9.
• Buprenorphine products (Suboxone, Subutex, Belbuca): the naltrexone component of Suboxone overlaps mechanistically; concurrent use is contraindicated.
• Thyroxine (levothyroxine): some LDN users with Hashimoto's thyroiditis report a reduction in thyroid antibody titers, which may alter levothyroxine requirements. Thyroid function should be checked at month 3 in patients on stable levothyroxine therapy 15.
• Immunosuppressants (methotrexate, azathioprine, mycophenolate): no pharmacokinetic interaction documented, but LDN's immune-modulating effects could theoretically counteract the desired immunosuppression. A specialist's input is appropriate before combining these drugs 16.

No cytochrome P450 interactions have been identified for naltrexone at any dose in FDA pharmacokinetic data 5.

Special Populations in Ohio

Patients with a History of Opioid Use Disorder

Naltrexone at full dose (50 mg) is an FDA-approved OUD treatment. At 1.5 mg to 4.5 mg, it retains receptor affinity. Ohio patients in OUD recovery who are opioid-free for at least 7 to 10 days may safely use LDN for a comorbid inflammatory condition, but the prescriber must confirm complete opioid clearance with a urine drug screen before initiating 17.

Pediatric Patients in Ohio

The Smith et al. 2011 pediatric Crohn's disease trial used 4.5 mg LDN in children ages 8 to 17 and reported no serious adverse events 3. Ohio prescribers treating pediatric patients should obtain parental consent and document that first-line Crohn's therapies (aminosalicylates, corticosteroids) were tried first. No Ohio-specific pediatric prescribing rule restricts LDN in minors, but most telehealth platforms restrict scheduling to adults 18 and older. An in-person pediatric gastroenterologist visit is the more common route for pediatric cases in Ohio.

Patients Over 65

Renal clearance of naltrexone and its active metabolite 6-beta-naltrexol decreases with age. A conservative starting dose of 1.5 mg nightly with slower titration (extending each phase to 4 weeks instead of 2) is appropriate for Ohio patients over 65. No geriatric-specific LDN dosing trial has been published as of 2025, but the FDA's naltrexone prescribing information notes that elderly patients may require dose adjustment based on renal function 5.